Recombinant outer membrane vesicles as a novel adjuvant for a malaria vaccine
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93018C00038
- Awardee
-
Versatope Therapeutics Inc. UEI VSMPM3EGYYA6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $450,000
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Pre-Solicitation · PHS20181 · Posted Jun 29, 2017
- Contract value 100% obligated
- $450,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Lowell, MA 01852, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $450,000 |
About this award
This is a $450,000.00 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institutes of Health (NIH) to Versatope Therapeutics Inc., a for-profit biotechnology company. The contract is for the development of a novel adjuvant for a malaria vaccine, using Versatope's recombinant outer membrane vesicle (ROMV) technology. The original solicitation was part of the NIH and Centers for Disease Control and Prevention (CDC) SBIR Program, which seeks to stimulate technological innovation and increase the commercial application of federally-supported research. The contract is a definitive, firm fixed-price agreement to advance Versatope's work on ROMV-based vaccines for infectious diseases like malaria. Versatope has also received several other SBIR grants from NIH and CDC to develop innovative vaccine candidates.
Quick answers
Who was awarded contract 75N93018C00038?
75N93018C00038 was awarded to Versatope Therapeutics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 22, 2018.
How much is contract 75N93018C00038 worth?
The government has obligated $450,000 on 75N93018C00038.
Was contract 75N93018C00038 competed?
The extent of competition for 75N93018C00038 was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award